We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$6.75B
AUM Growth
+$53.7M
Cap. Flow
+$290M
Cap. Flow %
4.3%
Top 10 Hldgs %
73.15%
Holding
41
New
5
Increased
16
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$61.6M
2
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$42.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$40.4M
4
APLS
Apellis Pharmaceuticals
APLS
+$28M
5
KRYS icon
Krystal Biotech
KRYS
+$26.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$13.3M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$5.45M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Miscellaneous 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$764M 11.33%
7,000,000
– –
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$733M 10.87%
11,111,111
+486,111
+5% +$28M
UTHR icon
3
United Therapeutics
UTHR
$21.5B
$643M 9.53%
2,870,000
+5,000
+0.2% +$1.23M
SRPT icon
4
Sarepta Therapeutics
SRPT
$2.19B
$503M 7.46%
3,650,000
+475,000
+15% +$61.6M
ARGX icon
5
argenx
ARGX
$61.3B
$480M 7.11%
1,287,500
+21,945
+2% +$8.12M
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12.1B
$404M 5.99%
1,666,666
+6,666
+0.4% +$1.82M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12.5B
$384M 5.69%
3,945,000
+389,445
+11% +$40.4M
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
$365M 5.41%
1,801,906
-83,094
-4% -$13.3M
ASND icon
9
Ascendis Pharma A/S
ASND
$15.8B
$357M 5.29%
3,325,000
+225,000
+7% +$25.7M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$303M 4.49%
27,300,000
+500,000
+2% +$6.16M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$31.9B
$221M 3.28%
1,105,000
– –
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$207M 3.06%
5,555,555
– –
XENE icon
13
Xenon Pharmaceuticals
XENE
$5.45B
$175M 2.6%
4,900,000
– –
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$165M 2.45%
6,800,000
+50,000
+0.7% +$1.09M
KRYS icon
15
Krystal Biotech
KRYS
$9.97B
$140M 2.08%
1,750,000
+340,000
+24% +$26.7M
KYMR icon
16
Kymera Therapeutics
KYMR
$9.41B
$114M 1.69%
3,855,000
+5,000
+0.1% +$161K
DICE
17
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$113M 1.68%
3,950,000
+1,424,445
+56% +$42.2M
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
$89.8M 1.33%
10,300,000
– –
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.09B
$86.9M 1.29%
10,420,000
+1,370,000
+15% +$13.2M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.62B
$56M 0.83%
2,650,000
– –
NUVL
21
DELISTED
Nuvalent
NUVL
$49.3M 0.73%
1,888,888
+333,333
+21% +$9.86M
IOVA icon
22
Iovance Biotherapeutics
IOVA
$4.24B
$42.9M 0.64%
7,020,000
– –
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$38.5M 0.57%
2,510,000
+460,000
+22% +$10.1M
KURA icon
24
Kura Oncology
KURA
$1.01B
$38M 0.56%
3,105,000
– –
MNKD icon
25
MannKind Corp
MNKD
$1.14B
$37.3M 0.55%
9,100,000
– –
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Avoro Capital Advisors held 41 positions worth $6.75B, up 0.8% from $6.69B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors deployed $290M of net new capital in Q1 2023, opening 5 new positions and adding to 16 existing holdings. Its largest new stake was Verrica Pharmaceuticals: 265,000 shares worth $17.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $13.3M trimmed.

  • Avoro Capital Advisors's largest Q1 2023 buy was Verrica Pharmaceuticals: 265,000 shares worth $17.2M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q1 2023, an estimated $61.6M increase.
  • Avoro Capital Advisors's biggest Q1 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $13.3M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $6.75B portfolio in Q1 2023.
  • Avoro Capital Advisors opened 5 new positions and closed 0 in Q1 2023.
  • Avoro Capital Advisors's portfolio value rose 0.8% quarter-over-quarter to $6.75B.

Based on Avoro Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.